Pulmonary immune disorders encompass a diverse spectrum of conditions in which the body’s immune system contributes to inflammation, injury, or dysfunction within the lungs. These disorders may arise from autoimmune processes, hypersensitivity reactions, or immune deficiencies that increase susceptibility to infections. Common examples include sarcoidosis, hypersensitivity pneumonitis, autoimmune-related interstitial lung diseases, and pulmonary manifestations of systemic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Pulmonary immune disorders can manifest with persistent cough, breathlessness, chest pain, or recurrent infections, and diagnosis often requires a combination of imaging, lung biopsies, bronchoalveolar lavage, and immunologic testing to establish underlying mechanisms. Management strategies vary according to the condition but frequently involve immunosuppressive therapies, including corticosteroids, biologics, or other disease-modifying agents to control inflammation and prevent progressive lung damage. Supportive measures such as pulmonary rehabilitation, infection prevention, and monitoring for drug-related toxicity also play a crucial role in patient care. Multidisciplinary collaboration among pulmonologists, immunologists, and rheumatologists ensures comprehensive evaluation and tailored treatment planning. Research in pulmonary immune disorders is advancing rapidly, with novel biomarkers, targeted biologics, and personalized immunomodulatory approaches showing promise in improving outcomes. By combining accurate diagnosis, effective immunotherapy, and long-term monitoring, the management of pulmonary immune disorders seeks to preserve lung function, minimize exacerbations, and enhance quality of life, highlighting the importance of immune regulation in maintaining respiratory health.
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Susceptibility to SARS-CoV-2 infection and nasal air conditioning ability
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Comparative evaluation of DECAF and BAP 65 scores in predicting outcomes of COPD exacerbations among in patients at Vicente Sotto Memorial Medical Center
Allanys Joy Q Pino, Vicente Sotto Memorial Medical Center, Philippines
Title :
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States
Title : Personalized and precision Medicine (PPM) as a unique healthcare model through biodesign driven and inspired biotech, translational applications and pulmonology related marketing to secure the human healthcare, wellness and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation